Bempedoic acid and bempedoic–ezetimibe are now indicated to prevent myocardial infarction and cardiovascular procedures in both primary- and secondary-prevention patients regardless of statin use.
Researchers at DZNE provide evidence that traces of the widely used PFAS chemicals in human blood are associated with unfavorable lipid profiles and thus with an increased risk of cardiovascular diseases.
Semaglutide improved MASLD in this population, and weight loss associated with its use resulted in no significant changes in physical function, according to two presentations at CROI.